Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Adolescents

Completed · Phase 2/Phase 3

Conditions studied: HIV

In brief

The primary objective of this study is to evaluate the safety and tolerability of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in HIV-infected virologically suppressed adolescents 12 to \< 18 years of age.

Key facts

Study ID

NCT02276612

Run by

Gilead Sciences

People needed

60

Starts

2014-12-03

Expected to finish

2017-10-23

Last updated by the study team

2018-11-19

Who can join

Age: 12 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Study site — Tampa, Florida, United States
• Study site — Detroit, Michigan, United States
• Study site — New York, New York, United States
• Study site — Memphis, Tennessee, United States
• Study site — Cape Town, South Africa
• Study site — Johannesburg, South Africa
• Study site — Soweto, South Africa

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.